L & S Advisors Inc Fate Therapeutics Inc Transaction History

L & S Advisors Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $524,863 - $899,552	24,946 New	24,946 $559,000
Q1 2022 May 11, 2022	SELL	$29.67 - $60.28 $756,970 - $1.54 Million	-25,513 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$47.84 - $64.34 $402,525 - $541,356	8,414 Added 49.21%	25,513 $1.49 Million
Q3 2021 Nov 09, 2021	SELL	$59.27 - $95.73 $328,829 - $531,110	-5,548 Reduced 24.5%	17,099 $1.01 Million
Q2 2021 Aug 12, 2021	BUY	$67.25 - $92.52 $33,826 - $46,537	503 Added 2.27%	22,647 $1.97 Million
Q1 2021 May 10, 2021	SELL	$72.16 - $117.4 $171,380 - $278,825	-2,375 Reduced 9.69%	22,144 $1.83 Million
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $99,110 - $262,671	-2,602 Reduced 9.59%	24,519 $2.23 Million
Q3 2020 Nov 13, 2020	BUY	$30.41 - $40.5 $148,370 - $197,599	4,879 Added 21.94%	27,121 $1.08 Million
Q2 2020 Aug 13, 2020	BUY	$20.21 - $35.23 $81,082 - $141,342	4,012 Added 22.01%	22,242 $763,000
Q1 2020 May 13, 2020	BUY	$17.28 - $31.88 $315,014 - $581,172	18,230 New	18,230 $405,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $161M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of L & S Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on L & S Advisors Inc with notifications on news.